World Peptide Foundation · Films & references
Peptides in 2™ series
Two-minute journeys through peptide discovery, the people behind the science, and what happens inside the body. Every episode has a place to explore the evidence beyond the film.
Episode 01 · 2 minutes · English
Exenatide: an extraordinary beginning
From a Gila monster peptide to a diabetes medicine: meet exendin-4, follow the development of exenatide, and explore GLP-1 receptor signaling.
English narration and captions. Translated subtitles are not yet available for this episode.
Behind the film: references & context
These sources support the episode’s discovery history, clinical context, and mechanism. Listing sources does not imply an independent scientific review or an endorsement by their authors.
- 1. Original discovery paper · Eng and colleagues, 1992
Isolation and characterization of exendin-4 from Heloderma suspectum venom.
- 2. Discovery history · U.S. Department of Veterans Affairs
John Eng and the Bronx VA research connection.
- 3. Exenatide (AC2993) · Human clinical study
Published human research on glucose control in type 2 diabetes.
- 4. Byetta · U.S. prescribing information
Indication, mechanism, pharmacokinetics, adverse reactions, warnings, and precautions.
- 5. Byetta · 2005 FDA approval announcement
Historical manufacturer announcement from Amylin and Lilly; identified as a company source.
- 6. Bydureon BCise · U.S. prescribing information
Extended-release exenatide has formulation-specific labeling and warnings.
Read the English transcript
The unexpected beginning
The first approved GLP-1 medicine has an extraordinary origin: a peptide found in the venom of a Gila monster.
Bronx, New York · 1992
In 1992, John Eng and colleagues at the Bronx Veterans Affairs Medical Center reported exendin-four. It mimics a hormone we already make, GLP-1, but resists breakdown for longer.
From discovery to medicine
Researchers developed a synthetic version: exenatide, also called AC2993 during development. Amylin and Eli Lilly brought it to patients as Byetta, approved in the United States in 2005 for type two diabetes.
Into the circulation
After injection beneath the skin, exenatide moves from the surrounding tissue into the circulation. It travels through the body and binds to GLP-1 receptors, activating signals inside responsive cells.
A glucose-dependent signal
In pancreatic beta cells, that signal helps release insulin when glucose is elevated. Insulin then helps the body manage blood sugar. Exenatide also reduces inappropriately elevated glucagon, a hormone that tells the liver to release glucose.
What changes in the body
It slows stomach emptying, too. Together, these effects improve glucose control. Weight loss can occur, but Byetta’s approval is for diabetes. Later extended-release formulations include Bydureon and Bydureon BCise.
Benefits need context
This is a medicine, not a risk-free shortcut. Nausea and vomiting can occur. Important concerns include pancreatitis, dehydration-related kidney problems, and low blood sugar when combined with insulin or certain diabetes medicines. Suitability depends on the person and formulation.
The next question
Explore the sources and studies at World Peptide Foundation. This is Peptides in 2. Every experience matters.
Educational information, not medical advice. The film is a brief introduction, not a complete account of benefits, risks, or prescribing requirements. Scientific research and self-reported observations remain distinct forms of information. WPF does not sell peptides.
Production: AI-generated narration and illustrative footage; molecular and body diagrams are schematic and not to scale. Historical photographs: Gila monster — John Kellam/BLM, via U.S. Fish & Wildlife Service; Bronx VA Medical Center — Veterans Health, via Wikimedia Commons (public domain).
Episode notes published October 6, 2026. Suggest a correction.